Treatment with nab-paclitaxel plus gemcitabine demonstrated statistically significant improvements across all endpoints vs gemcitabine alone, including OS (primary endpoint, median = 8.5 vs 6.7 months, HR = 0.72, 95% confidence interval = 0.62 to 0.83, P <.
#Pancrea tabs plus trial
These results led to an international phase III trial (MPACT,, trial number NCT00844649) in which 861 patients with metastatic pancreatic cancer were randomly assigned to receive nab-paclitaxel plus gemcitabine at the recommended doses from the phase I/II study ( nab-paclitaxel 125mg/m 2 plus gemcitabine 1000mg/m 2 on days 1, 8, and 15 of each 28-day cycle) or gemcitabine alone ( 17). A 2011 report revealed encouraging initial findings for patients with metastatic pancreatic adenocarcinoma treated at the maximum tolerated dose of nab-paclitaxel plus gemcitabine in a phase I/II trial: a median OS of 12.2 months, an overall response rate by Response Evaluation Criteria In Solid Tumors (RECIST) of 48%, and a median progression-free survival of 7.9 months ( 16). Nab-Paclitaxel (, Celgene Corporation, Summit, NJ) is an albumin-based formulation of paclitaxel that has demonstrated clinical benefit over solvent-based paclitaxel in patients with metastatic breast cancer ( 14) and non–small cell lung cancer ( 15). 001), although FOLFIRINOX was also associated with a marked potential for toxicity ( 5, 6). 038, 12-month OS rates of 23% vs 17%) and a phase II/III trial that found a statistically significant OS benefit for leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX, median = 11.1 vs 6.8 months, HR = 0.57, P <. In fact, until recently, only two trials had demonstrated statistically significant improvements in OS over gemcitabine for patients with this disease: a phase III study that showed a modest benefit for patients receiving gemcitabine plus erlotinib (median = 6.24 vs 5.91 months, hazard ratio = 0.82, P =. Experimental treatment arms have failed to statistically significantly improve OS over gemcitabine in numerous phase III trials ( 7–13). Median overall survival (OS) for patients who received gemcitabine monotherapy for advanced pancreatic cancer in key trials has ranged from 5.7 to 6.8 months ( 2, 5, 6). Gemcitabine monotherapy became a standard first-line treatment option for metastatic pancreatic cancer after it demonstrated superior clinical benefit over 5-fluorouracil ( 2–4). Among all cancer types, pancreatic cancer ranks 11th in incidence but fourth in mortality ( 1). That’s just 30 minutes a day, five days a week.Pancreatic cancer is one of the deadliest tumor types, accounting for approximately 7% of all cancer deaths in the United States ( 1). Regular physical activity means getting at least 150 minutes a week of brisk walking or a similar activity. A small amount of weight loss means around 5% to 7% of your body weight, just 10 to 14 pounds for a 200-pound person. If you have prediabetes, losing a small amount of weight if you’re overweight and getting regular physical activity can lower your risk for developing type 2 diabetes. You can get a simple blood sugar test to find out if you have prediabetes. Race and ethnicity are also a factor: African Americans, Hispanic/Latino Americans, American Indians, Pacific Islanders, and some Asian Americans are at higher risk. Ever having gestational diabetes (diabetes during pregnancy) or giving birth to a baby who weighed more than 9 pounds.Being physically active less than 3 times a week.Having a parent, brother, or sister with type 2 diabetes.
The good news: prediabetes can be reversed. It’s important to talk to your doctor about getting your blood sugar tested if you have any of the risk factors for prediabetes, which include: You can have prediabetes for years but have no clear symptoms, so it often goes undetected until serious health problems such as type 2 diabetes show up. Eventually your pancreas can’t keep up, and your blood sugar rises, setting the stage for prediabetes-and type 2 diabetes down the road. Your pancreas makes more insulin to try to get cells to respond. If you have prediabetes, the cells in your body don’t respond normally to insulin. Insulin is a hormone made by your pancreas that acts like a key to let blood sugar into cells for use as energy. The good news is that if you have prediabetes, the CDC-led National Diabetes Prevention Program can help you make lifestyle changes to prevent or delay type 2 diabetes and other serious health problems. Of those with prediabetes, more than 80% don’t know they have it. Prediabetes puts you at increased risk of developing type 2 diabetes, heart disease, and stroke.
Approximately 96 million American adults-more than 1 in 3-have prediabetes. Prediabetes is a serious health condition where blood sugar levels are higher than normal, but not high enough yet to be diagnosed as type 2 diabetes.
0 kommentar(er)
